Copanlisib Produces Prolonged Responses in Lymphoma [News in Brief]

More than half of patients respond to the PI3K inhibitor, which may be safer than idelalisib.

from Cancer via ola Kala on Inoreader http://ift.tt/2lh8QND
via IFTTT